Imipenem/cilastatin (1.5 g daily) versus Meropenem (3.0 g daily) in Patients with Intra-abdominal Infections: Results of a Prospective, Randomized, Multicentre Trial

References

• Meakins J L, Solomkin J S, Allo M D, Dellinger E P, Howard R J, Simmons R L. A proposed classification of intra-abdominal infections. Arch Surg 1984; 119: 1372–8
   PubMedGoogle Scholar
• Nichols R L. Intraabdominal infections: An overview. Rev Infect Dis 1985; 7(Suppl 4)S709–15
   PubMedGoogle Scholar
• Levison M E, Bush L M. Peritonitis and other intra-abdominal infections. Principles and practice of infectious diseases, GL. Mandell. Churchill Livingstone, New York 1990; 636–70
   Google Scholar
• Bohnen J MA, Mustard R A, Oxholm S E, Schouten B D. APACHE II score and abdominal sepsis-A prospective study. Arch Surg 1988; 123: 225–9
   PubMedGoogle Scholar
• Geroulanos S J. Antibiotics and the abdomen. Curr Opin Infect Dis 1994; 7(Suppl 1)S17–22
   Google Scholar
• Kager L, Nord C E. Imipenem/cilastatin in the treatment of intraabdominal infections: A review of worldwide experience. Rev Infect Dis 1985; 7(Suppl 3)S518–21
   PubMedGoogle Scholar
• Wilson S E. Carbapenem: monotherapy in intra-abdominal sepsis. Scand J Infect Dis Suppl 1995; 96: 28–33
   PubMedGoogle Scholar
• Condon R E, Walker A P, Sirinek K R, White P W, Fabian T C, Nichols R L, Wilson S E. Meropenem versus tobramycin plus clindamicyn for treatment of intraabdominal infections: results of a prospective, randomized, double-blind clinical trial. Clin Infect Dis 1995; 21: 544–50
   PubMed Web of Science ®Google Scholar
• Balfour J A, Bryson H M, Brogden R N. Imipenem/cilastatin: An update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections. Drugs 1996; 51: 99–136
   PubMed Web of Science ®Google Scholar
• Kropp H, Gerckens L, Sundelof J G, Kahan F M. Antibacterial activity of imipenem: The first thienamycin antibiotic. Rev Infect Dis 1985; 7(Suppl 3)S389–410
   PubMedGoogle Scholar
• Norby S R. Imipenem/cilastatin-rationale for a fixed combination. Rev Infect Dis 1985; 7(Suppl 3)S446–51
   Google Scholar
• Solomkin J S, Dellinger E P, Christou N V, Busuttil R W. Results of a multicenter trial comparing imipenem/cilastatin to tobramycin/clindamycin for intra-abdominal infections. Ann Surg 1990; 212: 581–91
   PubMed Web of Science ®Google Scholar
• Jones R N, Aldridge K E, Allen S D, Barry A L, Fuchs P C, Gerlach E H, Pfaller M A. Multicenter in vitro evaluation of SM-7338, a new carbapenem. Antimicrob Agents Chemother 1989; 33: 562–5
   PubMed Web of Science ®Google Scholar
• Visser M R, Hoepelman I M, Beumer H, Rozenberg-Arska M, Verhoef J. Comparative in vitro antibacterial activity of the new carbapenem meropenem (SM-7338). Eur J Clin Microbiol Infect Dis 1989; 8: 1061–4
   PubMed Web of Science ®Google Scholar
• Geroulanos S J. and the Meropenem Study Group. Meropenem versus imipenem/cilastatin in intra-abdominal infections requiring surgery. J Antimicrob Chemother 1995; 36(Suppl A)191–205
   PubMed Web of Science ®Google Scholar
• Brismar B, Malmborg A S, Tunevall G, Lindren V, Bergman L, Mentaing L O. Meropenem versus imipenem/cilastatin in the treatment of intra-abdominal infections. J Antimicrob Chemother 1995; 35: 139–48
   PubMed Web of Science ®Google Scholar
• Harabe E, Kawai Y, Kanazawa K, Otsuki M, Nishino T. In vitro and in vivo antibacterial activities of meropenem, a new carbapenem antibiotic. Drugs Exp Clin Res 1992; 18: 37–46
   PubMedGoogle Scholar
• Edwards J R. Meropenem: a microbiological overview. J Antimicrob Chemother 1995; 36(Suppl A)1–17
   PubMed Web of Science ®Google Scholar
• Norrby S R, Björnegåed B, Feber F, Jones K H. Pharmacokinetics of imipenem in healthy volunteers. J Antimicrob Chemother 1983; 12(Suppl D)109–24
   PubMed Web of Science ®Google Scholar
• Kelly H C, Hutchison M, Haworth S J. A comparison of the pharmacokinetics of meropenem after administration by intravenous injection over 5 min. and intravenous infusion over 30 min. J Antimicrob Chemother 1995; 36(Suppl A)35–41
   PubMed Web of Science ®Google Scholar
• Knaus W A, Draper E A, Wagner D P, Zimmerman J E. APACHE II: A severity of disease classification system. Cril Care Med 1985; 13: 818–29
   PubMed Web of Science ®Google Scholar
• White R, Friedrich L, Burgess D, Warkentin D, Bosso J. Comparative in vitro pharmacodynamic of imipenem and meropenem against Pseudomonas aeruginosa. Antimicrob Agents Chemother 1996; 40: 904–8
   PubMed Web of Science ®Google Scholar
• Norrby S R, Newell P A, Faulkner K L, Lesky W. Safety profile of meropenem: international clinical experience based on the first 3125 patients treated with meropenem. J Antimicrob Chemother 1995; 36(Suppl A)207–23
   PubMed Web of Science ®Google Scholar
• Toyoguchi T, Nakagawa Y, Watanabe H. Nephrotoxicity and drug interaction of vancomycin (1). Folia Pharmacol Jpn 1996; 107: 53–66
   PubMedGoogle Scholar
• Markewitz A, Hammer C, Pfeiffer M, Zahn S, Drechsel J, Reichenspurner H, Reichart B. Reduction of cyclosporine-in-duced nephrotoxicity by cilastatin following clinical heart transplantation. Transplantation 1994; 57: 865–70
   PubMed Web of Science ®Google Scholar